Daiken Biomedical Co., Ltd.
Daiken Biomedical Co., Ltd. engages in the research and development of healthy food products. The company is based in Taipei, Taiwan. Daiken Biomedical Co., Ltd. is a subsidiary of Sunfun Info Co., Ltd.
Daiken Biomedical Co., Ltd. (7780) - Total Liabilities
Latest total liabilities as of September 2025: NT$304.81 Million TWD
Based on the latest financial reports, Daiken Biomedical Co., Ltd. (7780) has total liabilities worth NT$304.81 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Daiken Biomedical Co., Ltd. - Total Liabilities Trend (2022–2024)
This chart illustrates how Daiken Biomedical Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Daiken Biomedical Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Daiken Biomedical Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Extek Technology Co. Ltd. A
SHE:301399
|
China | CN¥188.59 Million |
|
Cahya Mata Sarawak Berhad
PINK:CHYMF
|
USA | $801.52 Million |
|
Socep Constant
RO:SOCP
|
Romania | RON378.29 Million |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
USA | $20.91 Million |
|
Hangzhou Flariant Co Ltd
SHG:605566
|
China | CN¥555.35 Million |
|
Bintulu Port Holdings Bhd
KLSE:5032
|
Malaysia | RM1.36 Billion |
|
Prim S.A.
MC:PRM
|
Spain | €75.24 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down Daiken Biomedical Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daiken Biomedical Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daiken Biomedical Co., Ltd. (2022–2024)
The table below shows the annual total liabilities of Daiken Biomedical Co., Ltd. from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$230.81 Million | -53.64% |
| 2023-12-31 | NT$497.85 Million | +64.45% |
| 2022-12-31 | NT$302.74 Million | -- |